Disease · MONDO_0019460
acute leukemia of ambiguous lineage
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. acute leukemia of ambiguous lineage. Diseases, record MONDO_0019460. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019460
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- acute leukaemia of indeterminate lineage, acute leukemia of indeterminate lineage, hybrid acute leukaemia, hybrid acute leukemia, mixed lineage acute leukaemia, mixed lineage acute leukemia
- Open Targets
- Highest stage of its drugs
- Phase 2, for 21 of its 31 drugs, from ClinicalTrials.gov and TTD
- Open Targets
Drugs31
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CYTARABINE | CHEMBL803 | Small molecule | Phase 2 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| METHOTREXATE | CHEMBL34259 | Small molecule | Phase 2 | ClinicalTrials.gov | 4 | 4 | 3 | Drugs and targets |
| PREDNISOLONE | CHEMBL131 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| PREDNISONE | CHEMBL635 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| REVUMENIB | CHEMBL4650827 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| VINCRISTINE SULFATE | CHEMBL501867 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ASPARAGINASE | CHEMBL2108989 | Enzyme | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CALASPARGASE PEGOL | CHEMBL2108728 | Enzyme | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DAUNORUBICIN | CHEMBL178 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 31
See all 31 drugsTargets57
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 5 | Glucocorticoid receptor agonist | Phase 2 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| TOP2A | DNA topoisomerase 2-alpha | 4 | DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor | Phase 2 | https://conductscience.org/library/genes/7153 | Drugs and targets |
| CD3D | T cell surface glycoprotein CD3 | 2 | T cell surface glycoprotein CD3 binding agent; T cell surface glycoprotein CD3 cross-linking agent | Phase 2 | https://conductscience.org/library/genes/915 | Drugs and targets |
| CD3E | T cell surface glycoprotein CD3 | 2 | T cell surface glycoprotein CD3 binding agent; T cell surface glycoprotein CD3 cross-linking agent | Phase 2 | https://conductscience.org/library/genes/916 | Drugs and targets |
| CD3G | T cell surface glycoprotein CD3 | 2 | T cell surface glycoprotein CD3 binding agent; T cell surface glycoprotein CD3 cross-linking agent | Phase 2 | https://conductscience.org/library/genes/917 | Drugs and targets |
| DNMT1 | DNA (cytosine-5)-methyltransferase 1 | 2 | DNA (cytosine-5)-methyltransferase 1 inhibitor | Phase 1 | https://conductscience.org/library/genes/1786 | Drugs and targets |
| DNMT3A | DNA (cytosine-5)-methyltransferase 3A | 2 | DNA (cytosine-5)-methyltransferase 3A inhibitor | Phase 1 | https://conductscience.org/library/genes/1788 | Drugs and targets |
| POLA1 | DNA polymerase (alpha/delta/epsilon) | 2 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 2 | https://conductscience.org/library/genes/5422 | Drugs and targets |
| POLA2 | DNA polymerase (alpha/delta/epsilon) | 2 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 2 | https://conductscience.org/library/genes/23649 | Drugs and targets |
| POLD1 | DNA polymerase (alpha/delta/epsilon) | 2 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 2 | https://conductscience.org/library/genes/5424 | Drugs and targets |
1 to 10 of 57
See all 57 targetsTrials9
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00844298 | Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | Phase 2 | 91 | 2015-09-07 | Leukemia | CYTARABINE, DAUNORUBICIN HYDROCHLORIDE, ETOPOSIDE, LEUCOVORIN CALCIUM, METHOTREXATE, NILOTINIB, PREDNISOLONE, VINCRISTINE SULFATE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT04988555 | A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | Phase 1/2 | 606 | Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes | ENZOMENIB | Its record names the disease | ClinicalTrials.gov | |
| NCT05761171 | A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia | Phase 2 | 78 | Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Refractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged, Refractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia, Refractory Mixed Phenotype Acute Leukemia | CALASPARGASE PEGOL, CYTARABINE, FLUDARABINE PHOSPHATE, HYDROCORTISONE SODIUM SUCCINATE, METHOTREXATE, PREDNISOLONE, PREDNISONE, REVUMENIB, VINCRISTINE SULFATE | Its record names the disease | ClinicalTrials.gov | |
| NCT03194932 | Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage | Phase 1 | 62 | Acute Myeloid Leukemia | AZACITIDINE, CYTARABINE, IDARUBICIN, VENETOCLAX | Its record names the disease | ClinicalTrials.gov | |
| NCT04440267 | Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage | Phase 2 | 50 | Acute Leukemia of Ambiguous Lineage | ASPARAGINASE, CYCLOPHOSPHAMIDE, DAUNORUBICIN, DEXAMETHASONE, MERCAPTOPURINE, METHOTREXATE, PREDNISONE, VINCRISTINE | Its record names the disease | ClinicalTrials.gov | |
| NCT06991920 | Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage | Not applicable | 50 | Adult ALL, MPAL | BLINATUMOMAB, VENETOCLAX | Its record names the disease | ClinicalTrials.gov | |
| NCT04898894 | Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | Phase 1 | 37 | Acute Leukemia of Ambiguous Lineage in Relapse, Acute Myeloid Leukemia, in Relapse, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Myeloid Leukemia | SELINEXOR, VENETOCLAX | Its record names the disease | ClinicalTrials.gov | |
| NCT06177067 | Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | Phase 1 | 24 | Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Leukemia of Ambiguous Lineage | AZACITIDINE, REVUMENIB, VENETOCLAX | Its record names the disease | ClinicalTrials.gov | |
| NCT06474663 | A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias | Phase 1 | 0 | Refractory Acute Leukemia, Relapsed Acute Leukemia | CLADRIBINE, CYTARABINE, DECITABINE, SORAFENIB | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials4
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019460
GET https://conductscience.org/api/diseases/v1/MONDO_0019460/drugs?page=2